Title:
【発明の名称】RNase L アクチベーター及びRSV感染の治療に有効なアンチセンスオリゴヌクレオチド
Document Type and Number:
Japanese Patent JP2000506384
Kind Code:
A
Abstract:
The invention concerns a compounds and methods for treating infection with Respiratory Syncytial Virus. The compounds comprise an antisense portion, which is complementary to a normally single stranded portion of the RSV antigenomic strand (the mRNA strand), a linker and a oligonucleotide activator of RNase L, a ubiquitous non-specific RNase. The method comprised forming a complex of an activated RNase L and the antisense molecule. The application teaches methods of determining which portions of the RSV antigenomic strand are normally single-stranded. The application teaches that an antisense oligonucleotide having the sequence of residues 8281-8299 of the RSV genome is particularly useful to practice the invention and provides in vitro results superior to those obtainable with the conventional drug of choice, ribavirin.
More Like This:
Inventors:
Torrens, Paul, F.
Silberman, Robert, H.
Sirino, Nick, M.
Lee Quinn
Xiao, Way
Silberman, Robert, H.
Sirino, Nick, M.
Lee Quinn
Xiao, Way
Application Number:
JP52956997A
Publication Date:
May 30, 2000
Filing Date:
February 14, 1997
Export Citation:
Assignee:
National Institutes of Health
The Cleveland Clinic Foundation
The Cleveland Clinic Foundation
International Classes:
C12N15/09; A61K31/00; A61K31/70; A61K31/7088; A61K48/00; A61P31/00; A61P31/14; C07H21/00; C12N15/00; C12N15/113; C12Q1/68; A61K38/00; C12R1/92; (IPC1-7): C12N15/09; A61K31/7088; A61K48/00; A61P31/14; C12Q1/68
Attorney, Agent or Firm:
Yusuke Hiraki (1 person outside)